Kinase News and Research

RSS

Kinexus releases new antibody microarray kit

Kinexus Bioinformatics Corporation, a world leader in functional proteomics research, announced today the release of its first Kinex antibody microarray kit with its latest generation KAM-850 chip.

27 Nov 2012

Paper illuminates importance of PKM2 in cancer development and progression

Researchers at The University of Texas MD Anderson Cancer Center have tracked down a cancer-promoting protein's pathway into the cell nucleus and discovered how, once there, it fires up a glucose metabolism pathway on which brain tumors thrive.

26 Nov 2012

Nonfunctional MED12 gene linked to chemotherapy resistance

Research published in Cell shows that people with tumors that have a nonfunctional version of the mediator 12 gene are resistant to drugs used to treat lung and colon cancer such as gefitinib.

26 Nov 2012

Tivantinib holds personalized therapy promise in HCC

Tivantinib is an effective second-line therapy for hepatocellular carcinoma patients whose tumors exhibit high MET receptor tyrosine kinase expression, indicate phase II study results.

26 Nov 2012

UPR pathway helps tumor cells escape apoptosis during development of lymphoma

A pathway called the "Unfolded Protein Response," or UPR, a cell's way of responding to unfolded and misfolded proteins, helps tumor cells escape programmed cell death during the development of lymphoma.

21 Nov 2012

Regorafenib able to control resistant gastrointestinal stromal tumor

A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial.

21 Nov 2012

Acetylon's ective histone deacetylase inhibitors to be showcased at 54th ASH annual meeting

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced that its selective histone deacetylase (HDAC) inhibitors will be featured in five posters and one oral presentation at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place December 8-11, 2012, in Atlanta, Georgia.

21 Nov 2012

Study: Regular exercise before, during pregnancy could have beneficial effects for women

Contrary to popular thought, regular exercise before and during pregnancy could have beneficial effects for women that develop high blood pressure during gestation, human physiology professor Jeff Gilbert said, summarizing a new study by his research team that appears in the December issue of Hypertension, a journal of the American Heart Association.

16 Nov 2012

AKT1 genotype influences risk of psychotic disorders in cannabis users

The ability of cannabis to produce psychosis has long been an important public health concern. This concern is growing in importance as there is emerging data that cannabis exposure during adolescence may increase the risk of developing schizophrenia, a serious psychotic disorder. Further, with the advent of medical marijuana, a new group of people with uncertain psychosis risk may be exposed to cannabis.

15 Nov 2012

Scientists eliminate metastasis in laboratory experiments

In laboratory experiments, scientists have eliminated metastasis, the spread of cancer from the original tumor to other parts of the body, in melanoma by inhibiting a protein known as melanoma differentiation associated gene-9 (mda-9)/syntenin. More than 1 million cases of skin cancer are diagnosed each year in the U.S., and melanoma is the deadliest form.

15 Nov 2012

Scientists show how sorafenib can be dangerous to the heart

Scientists for the first time have evidence showing how a widely used type of "targeted" cancer drug can be dangerous to the heart.

7 Nov 2012

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

Turning off GSK-3α protein activity can prevent heart remodeling

When a person has a heart attack, portions of the heart muscle die in the next several days or even weeks if deprived of oxygen for long enough. The recovering heart slowly remodels itself, even fostering the growth of new blood vessels, in an attempt to regain some of its former function. But all too often, the remodeling is actually harmful, and the damaged heart is on an inevitable downward slide to heart failure.

6 Nov 2012

FDA approves Pfizer’s XELJANZ to treat rheumatoid arthritis

Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.

6 Nov 2012

Pfizer receives FDA approval for Xeljanz to treat rheumatoid arthritis

The U.S. Food and Drug Administration today approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.

6 Nov 2012

Researchers develop new technique to predict enzymes known to accelerate diseases

Predicting how atherosclerosis, osteoporosis or cancer will progress or respond to drugs in individual patients is difficult.

3 Nov 2012

Top-line results from Aerie Pharmaceuticals' AR-13324 Phase 2a study on glaucoma

Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive top-line results from its Phase 2a study evaluating AR-13324 for the treatment of glaucoma.

3 Nov 2012

Physicists to bring to market new drug-discovery tool using genetic sequencing

Today physicists at Wake Forest University and NanoMedica, their biotechnology company partner, received a $700,000 grant from the National Institutes of Health to bring to market a new drug-discovery tool using next-generation genetic sequencing.

3 Nov 2012

Virginia G. Piper, TESARO announce initiation of TSR-011 clinical trial for advanced cancer

TESARO, Inc. announced today that the first clinical trial of its proprietary Anaplastic Lymphoma Kinase (ALK) inhibitor, TSR-011, has commenced with the dosing of the first patient at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).

2 Nov 2012

Researchers unlock complex cellular mechanics that instruct glial progenitor cells to divide

In a new study appearing this month in the Journal of Neuroscience, researchers have unlocked the complex cellular mechanics that instruct specific brain cells to continue to divide. This discovery overcomes a significant technical hurdle to potential human stem cell therapies; ensuring that an abundant supply of cells is available to study and ultimately treat people with diseases.

2 Nov 2012

Kinase News and Research

Kinexus releases new antibody microarray kit

Paper illuminates importance of PKM2 in cancer development and progression

Nonfunctional MED12 gene linked to chemotherapy resistance

Tivantinib holds personalized therapy promise in HCC

UPR pathway helps tumor cells escape apoptosis during development of lymphoma

Regorafenib able to control resistant gastrointestinal stromal tumor

Acetylon's ective histone deacetylase inhibitors to be showcased at 54th ASH annual meeting

Study: Regular exercise before, during pregnancy could have beneficial effects for women

AKT1 genotype influences risk of psychotic disorders in cannabis users

Scientists eliminate metastasis in laboratory experiments

Scientists show how sorafenib can be dangerous to the heart

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Turning off GSK-3α protein activity can prevent heart remodeling

FDA approves Pfizer’s XELJANZ to treat rheumatoid arthritis

Pfizer receives FDA approval for Xeljanz to treat rheumatoid arthritis

Researchers develop new technique to predict enzymes known to accelerate diseases

Top-line results from Aerie Pharmaceuticals' AR-13324 Phase 2a study on glaucoma

Physicists to bring to market new drug-discovery tool using genetic sequencing

Virginia G. Piper, TESARO announce initiation of TSR-011 clinical trial for advanced cancer

Researchers unlock complex cellular mechanics that instruct glial progenitor cells to divide

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News